ArticleRMD open2025
Evaluation of spondyloarthritis-specific health utility based on ASAS health index (U-ASAS-HI) among the disease subtypes: an ancillary analysis from the ASAS-PerSpA study.
Article in RMD open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo compare the spondyloarthritis (SpA) specific universal health utility estimation from the ASAS health index (U-ASAS-HI) with the generic EuroQol-5D-3L (EQ-5D-3L) utility among SpA subtypes and to understand the contribution of health-, personal- and country-level factors to the U-ASAS-HI.
methodsAncillary analysis of the ASAS-PERipheral involvement in SpondyloArthritis (PerSpA) study including patients who completed both ASAS-HI and EQ-5D-3L. Correlations between U-ASAS-HI and EQ-5D-3L were tested overall and by subtype (axial SpA, peripheral SpA and psoriatic arthritis (PsA)). Health and contextual determinants of U-ASAS-HI were evaluated using multivariable linear mixed-effects models with country as level.
results4158 patients were included, mean age 44 (SD:13) and 61% male. Mean U-ASAS-HI was 0.44 (SD:0.30) and mean EQ-5D-3L was 0.71 (SD:0.21), with numerically minor differences between subtypes. Correlations between U-ASAS-HI and EQ-5D-3L were consistently strong between subgroups (range 0.74-0.76). Linear mixed-effects modelling showed health outcomes, including disease activity (axial spondyloarthritis disease activity score; β=-0.030, 95% CI -0.038 to -0.021), physical function (bath ankylosing spondylitis functional index; β=-0.044, 95% CI -0.048 to -0.041), anxiety/depression (EQ-5D-3L q5; β=-0.147, 95% CI -0.160 to -0.134) and fibromyalgia (fibromyalgia rapid screening tool; β=-0.068, 95% CI -0.083 to -0.053) were strong predictors of lower U-ASAS-HI. Additionally, female gender, PsA subtype, axial involvement, fatigue and having no employment were associated with lower U-ASAS-HI while older age and university education were associated with higher U-ASAS-HI. The random-effects model indicated an intraclass correlation coefficient of 6% in total variance attributable to differences between countries.
conclusionThe universal U-ASAS-HI captures the broad range of aspects relevant to valuing SpA health states across SpA subtypes. The lower absolute values of U-ASAS-HI reflect the wider disutility associated with SpA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.